Melanotan-2 Dosage: How It's Used

People searching for a Melanotan-2 dose are almost always looking for a number — how much, how often, how to ramp up. This page deliberately does not give one, and the reason isn’t squeamishness. With most peptides, dosing is a medical decision a prescriber individualizes and adjusts. With Melanotan-2 there is no prescriber and no legitimate product, so the “dose” being asked about is a forum convention applied to an unregulated injectable of unknown strength. Understanding why that framing is the actual hazard is more useful than any protocol you could copy.

Why Melanotan-2 has no real dose to give

A dose, in any meaningful sense, comes from somewhere: a clinical trial that established an effective and tolerable amount, an approved label, a prescriber matching it to a patient. Melanotan-2 has none of these inputs.

It has never completed Phase I, II, or III human trials. ClinicalTrials.gov lists no active or recruiting trials for Melanotan II in the US, and no Investigational New Drug application appears to be active. Because it is off-patent and has no commercial sponsor willing to fund the hundreds of millions of dollars that approval testing costs, that gap is not closing. The melanoma-risk question — whether chronically stimulating pigment cells in people who already have moles raises cancer risk — has never been resolved by trial data, which is one reason no regulator has a basis to approve it.

So when a forum lists “a typical starting dose,” it is not summarizing evidence. It is repeating a habit. There is no body of safety data behind the number, no monitoring built around it, and no one accountable if it is wrong for you.

The number is not the dangerous part — the vial is

Even if a Melanotan-2 protocol were sensible on paper, it would still be applied to a product nobody has verified.

Independent analysis makes this concrete. When researchers tested gray-market Melanotan-2, vials labeled 10 mg were found to contain actual peptide content ranging from roughly 4.32 to 8.84 mg. That is more than a two-fold spread between products carrying the same label. A user “carefully measuring a precise dose” from such a vial is measuring precisely against a number that may be wrong by half.

Concentration is only the first unknown. Gray-market injectables also vary in purity, in what else is in the powder, and in whether the vial was filled and handled under sterile conditions. Because Melanotan-2’s unapproved status means every batch circulates without standardized potency verification, there is no batch testing, no quality release, and no recall mechanism. This is the core point the spec calls the DIY danger: the “right dose” of an unverified, possibly contaminated product is still wrong, because you cannot know what you actually injected.

Note: This is why “just follow the standard protocol” fails as advice. A protocol assumes a known, consistent product. Melanotan-2 from the gray market is not that, so the protocol’s central assumption is missing before you start.

How Melanotan-2 is used — and why the route compounds the risk

Part of what makes Melanotan-2 distinct from other compounds is how it is administered in practice, and each route adds its own problem on top of the unknown-vial issue.

The traditional route is subcutaneous injection of reconstituted powder — which means a user is mixing a powder of unknown true mass with bacteriostatic water, drawing it up, and injecting it, with no pharmacist preparing or checking anything. Some users instead turn to nasal sprays marketed as “needle-free,” which trade the injection for even less dose predictability, since absorption through the nasal lining is erratic and the delivered amount is essentially uncontrolled.

There is also a cultural pattern specific to MT-2: a “loading then maintenance” mentality borrowed from tanning forums, where people push higher early to build pigment fast and then dose to top it up. Stacking more of an unverified peptide to chase a cosmetic result is exactly the behavior that links to the harms below — it maximizes exposure to a product no one has characterized.

What MT-2’s receptor profile means for dose-related effects

Melanotan-2 is a non-selective melanocortin agonist. It does not just hit MC1R, the receptor tied to pigmentation; it also activates other melanocortin receptors, including MC4R, which is involved in sexual arousal and appetite. This is why side effects like spontaneous erections, nausea, flushing, and appetite changes show up alongside tanning — they are not separate problems, they are the same molecule hitting receptors it was never refined to avoid.

This matters for the dosing question because those off-target effects are dose-related: more peptide means more non-selective receptor activation. Published case reports have linked Melanotan-2 use to melanoma, ischemic priapism, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome. European observational reporting and the EMA’s 2026 review have flagged severe nausea, hypertension, and other reactions. The takeaway is not “find the dose that avoids these” — it is that a non-selective agonist of unknown concentration cannot be titrated to safety by a layperson.

The contrast that exposes the whole problem: Scenesse

There is an FDA-approved melanocortin drug, and the comparison is clarifying. Afamelanotide — sold as Scenesse — completed a full regulated clinical program and was FDA-approved in October 2019 for phototoxic reactions in adults with erythropoietic protoporphyria, a rare light-sensitivity disorder. It is a selective MC1R agonist, delivered as a controlled-release implant placed by a specialist, with a defined dose, monitoring, and an approved indication.

As of April 2026, afamelanotide is the only MC1R-targeted melanocortin agonist with FDA approval for any indication, and Melanotan II has no approved indication anywhere in the world. That contrast is the answer to “what’s a safe MT-2 dose”: when a properly developed, selective, dosed version of this drug class exists for a real medical need, the case for self-injecting the non-selective, untested, unverified version for a tan collapses.

The legal and regulatory picture (current as of June 2026)

The 2026 federal changes are widely misread, so to be precise: Melanotan II was among 12 peptides removed from FDA Category 2 on April 15, 2026 — but removal from Category 2 does not place a substance on the 503A authorized bulks list, which requires a separate Pharmacy Compounding Advisory Committee review and FDA decision. A PCAC meeting is scheduled for July 23–24, 2026, and until that process concludes, compounding pharmacies are still not authorized to produce these peptides.

In plain terms: nothing about the 2026 changes created a legal route to obtain a prescribed, pharmacy-made Melanotan-2 dose. It remains not FDA-approved and illegal to sell for human use; it is sold as a “research chemical,” and a physician writing a prescription for it is operating outside the FDA regulatory framework. The FDA’s Office of Criminal Investigations issued multiple warning letters to suppliers marketing it for cosmetic use in early 2026, and it is also banned in competitive sport under the relevant WADA prohibited-substance category.

For the full mechanics of why no prescription pathway exists, see Melanotan-2 prescription status and how to get Melanotan-2 in the US — both of which reach the same conclusion from different angles.

So how is dosing decided for legitimate peptides?

It’s worth stating the contrast clearly, because it shows what’s missing here. For a legitimately prescribed peptide, dose is individualized to the person — their goal, labs, age, weight, and response — and set and adjusted over time by a licensed prescriber who monitors for adverse effects. The starting amount, any adjustment, and the decision to continue all sit with a clinician working from a known, quality-controlled product. Our peptide dosing guide walks through those general principles.

Melanotan-2 has none of that infrastructure. There is no prescriber setting the dose, no quality-controlled product to dose against, and no monitoring loop. That absence — not a missing magic number — is the honest answer to “what’s the Melanotan-2 dosage.”

The bottom line

The Melanotan-2 dose people are searching for doesn’t exist in any legitimate sense, and the closest available numbers are forum conventions applied to vials that independent testing shows can contain half their labeled peptide. Combine an unverified product, a non-selective receptor profile, injection or nasal routes with no clinical oversight, and a documented list of serious case-report harms, and the safest reading of the evidence is that there is no protocol that makes self-administered Melanotan-2 a calculated risk rather than an uncontrolled one.

If the underlying goal is a tan, regulated cosmetic options carry none of this uncertainty. If the interest is the science, that’s exactly what an approved, selective drug like Scenesse represents — developed, tested, and dosed the way Melanotan-2 never was.